scispace - formally typeset
Open AccessJournal ArticleDOI

SARS-CoV-2: a storm is raging.

Savannah F. Pedersen, +1 more
- 01 May 2020 - 
- Vol. 130, Iss: 5, pp 2202-2205
TLDR
Overall, this study characterized the cytokine storm in severe COVID-19 and provides insights into immune therapeutics and vaccine design and the authors found that respiratory distress on admission is associated with unfavorable outcomes.
Abstract
The pandemic coronavirus infectious disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is rapidly spreading across the globe. In this issue of the JCI, Chen and colleagues compared the clinical and immunological characteristics between moderate and severe COVID-19. The authors found that respiratory distress on admission is associated with unfavorable outcomes. Increased cytokine levels (IL-6, IL-10, and TNF-α), lymphopenia (in CD4+ and CD8+ T cells), and decreased IFN-γ expression in CD4+ T cells are associated with severe COVID-19. Overall, this study characterized the cytokine storm in severe COVID-19 and provides insights into immune therapeutics and vaccine design.

read more

Citations
More filters
Journal ArticleDOI

Vaccination against SARS-CoV-2 and disease enhancement - knowns and unknowns.

TL;DR: The in vivo evidence suggesting a theoretical risk of disease enhancement after vaccination with SARS- CoV and MERS-CoV vaccine candidates is reviewed and avenues to investigate the risk of vaccine-mediated disease enhancement both during pre-clinical and early clinical development are proposed.
Journal ArticleDOI

Battling COVID-19 Pandemic: Sphingosine-1-Phosphate Analogs as an Adjunctive Therapy?

TL;DR: To investigate the possible utility of using S1P analogs to treat COVID-19, it was shown that the treatment with sphingosine-1-phosphate receptor 1 analog, CYM5442, resulted in the significant dampening of the immune response upon H1N1 challenge in mice and improved survival of H 1N1 infected mice in combination with an antiviral drug.
Journal ArticleDOI

Exosomes contribution in COVID-19 patients' treatment.

TL;DR: In this paper, mesenchymal stromal/stem cells (MSCs), adipocyte MSCs, Ad-MSCs and adipose-derived stem cells (ADSCs) possessing potent immunomodulatory activities are proposed as a therapeutic option for the treatment of coronavirus disease 2019 (COVID-19).
Journal ArticleDOI

NLRP3 inflammasome activation in COVID-19: an interlink between risk factors and disease severity.

TL;DR: In this article, the authors focused on the occurrence of NLRP3 inflammasome activation in response to SARS-COV-2 infection, dysregulation of NLP3 activation events in the presence of several comorbidities, and the contribution of activated NLP-III inflammmasome to the severity of COVID-19, and available therapeutics for the treatment of such NLRP-III related diseases.
References
More filters
Journal ArticleDOI

A Novel Coronavirus from Patients with Pneumonia in China, 2019.

TL;DR: Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily, which is the seventh member of the family of coronaviruses that infect humans.
Related Papers (5)